Treventis Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$490K
- Investors
-
7
Treventis General Information
Description
Developer of disease-modifying small molecule drugs designed to identify the molecule that can enter the brain and neutralize both misfolded proteins. The company's drugs can identify compounds that potently block the progression of amyloid toxicity, enabling physicians to treat Alzheimer's patients without any side effects.
Contact Information
Website
www.treventis.comCorporate Office
- 60 Leonard Avenue 4KD472
- Toronto, Ontario M5T 0S8
- Canada
Corporate Office
- 60 Leonard Avenue 4KD472
- Toronto, Ontario M5T 0S8
- Canada
Treventis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Grant | 01-Jan-2023 | $490K | Completed | Pre-Clinical Trials | ||
| 5. Grant | 18-Oct-2022 | Completed | Pre-Clinical Trials | |||
| 4. Accelerator/Incubator | 01-Feb-2017 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | 21-Jan-2016 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 30-Jul-2012 | $4.41M | $4.96M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 10-Aug-2009 | $550K | $550K | Completed | Pre-Clinical Trials |
Treventis Comparisons
Industry
Financing
Details
Treventis Competitors (7)
One of Treventis’s 7 competitors is Cognition Therapeutics, a Formerly VC-backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Neurimmune | Formerly Accelerator/Incubator backed | Zurich, Switzerland | ||||
| NMD Pharma | Venture Capital-Backed | Aarhus, Denmark | ||||
| ProMIS Neurosciences | Corporation | Toronto, Canada |
Treventis Patents
Treventis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230357154-A1 | Butyrylcholinesterase compounds and use in diseases of the nervous system | Pending | 08-Aug-2019 | ||
| WO-2021026429-A1 | Butyrylcholinesterase compounds and use in diseases of the nervous system | Inactive | 08-Aug-2019 | ||
| AU-2015222903-A1 | Anti-amyloid compounds containing benzofurazan | Active | 27-Feb-2014 | ||
| AU-2015222903-B2 | Anti-amyloid compounds containing benzofurazan | Active | 27-Feb-2014 | ||
| CA-2977360-A1 | Anti-amyloid compounds containing benzofurazan | Active | 27-Feb-2014 | C07D271/12 |
Treventis Signals
Treventis Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| United States Department of War | Government | |||
| Congressionally Directed Medical Research Programs | Government | |||
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | |||
| Invest Nova Scotia | Venture Capital | Minority | ||
| Life Sciences Nova Scotia | Accelerator/Incubator | Minority |
Treventis FAQs
-
When was Treventis founded?
Treventis was founded in 2008.
-
Where is Treventis headquartered?
Treventis is headquartered in Toronto, Canada.
-
What is the size of Treventis?
Treventis has 18 total employees.
-
What industry is Treventis in?
Treventis’s primary industry is Drug Discovery.
-
Is Treventis a private or public company?
Treventis is a Private company.
-
What is Treventis’s current revenue?
The current revenue for Treventis is .
-
How much funding has Treventis raised over time?
Treventis has raised $5.06M.
-
Who are Treventis’s investors?
United States Department of War, Congressionally Directed Medical Research Programs, Johnson & Johnson Innovation - JLABS, Invest Nova Scotia, and Life Sciences Nova Scotia are 5 of 7 investors who have invested in Treventis.
-
Who are Treventis’s competitors?
Cognition Therapeutics, Alzheon, Neurimmune, NMD Pharma, and ProMIS Neurosciences are some of the 7 competitors of Treventis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process